Dr. Craig Hendrix will step down as director of the Division of Clinical Pharmacology, and Dr. Charles Flexner will serve as interim director effective January 15.
Dr. Craig Hendrix expertly led the Division of Clinical Pharmacology since 2015, and has been recognized for his leadership and program building for even longer. Prior to joining the Hopkins faculty in 1997, he served 13 years in the U.S. Air Force where he directed the program that provided clinical care and related research for over 1,000 HIV-positive servicemembers. In 1998, he became director of the division’s Drug Development Unit, a self-supporting early phase clinical trials resource, where he led over 125 clinical studies. Through NIH HIV clinical trial networks, he served as clinical pharmacologist for another 85 clinical trials, primarily of HIV pre-exposure prophylaxis. He has served on advisory committee for the World Health Organization, National Academy of Medicine, CDC Board of Scientific Counselors and numerous FDA Advisory Committees. His teaching and mentoring have been recognized with the DOM’s David M. Levine Mentoring Award and the Excellence in Teaching Award from the Johns Hopkins Alumni Association. Dr. Hendrix led the Clinical Pharmacology Training Program funded by the National Institute of General Medical Science since 2016 and serves as chairman of the American Board of Clinical Pharmacology, which accredits fellowship training programs and certifies board diplomates. Dr. Hendrix will continue teaching as Professor Emeritus and will continue leadership of an ongoing NIH multicenter HIV prevention trial and pay increased attention to a company he founded to develop novel HIV prevention drugs.
Dr. Charles Flexner is a Professor of Medicine in the Divisions of Clinical Pharmacology and Infectious Diseases, and a Professor of Pharmacology and Molecular Sciences and International Health. He is founder and director of the Long-Acting/Extended-Release Antiretroviral Research Resource Program, providing advice and support to international stakeholders including the NIH, World Health Organization (WHO), Bill and Melinda Gates Foundation and Unitaid. He is co-director of the JHU Baltimore- India HIV Clinical Trials Unit and deputy director of the Graduate Training Programs in Clinical Investigation. He also serves as Chief Scientific Officer of the Institute for Clinical and Translational Research and is a long-standing member, and the only pharmacologist, on the WHO Clinical Guidelines Development Group for Treatment and Prevention of HIV in Adults, Adolescents and Children. He is an expert on the basic and clinical pharmacology of drugs for HIV/AIDS and related infections, including viral hepatitis and tuberculosis and current research focuses on the discovery and development of new molecules and formulations for long-acting administration for the treatment and prevention of HIV and related infections.
Please join us in thanking Dr. Hendrix for his many years of leadership as well as Dr. Flexner for stepping in during this time of transition. The search for the permanent director is already underway.
